Industry: Pharmaceuticals, Biotechnology
APT is a clinical-stage company developing products to treat respiratory diseases. The company is developing steroid alternative therapies based on novel reformulations and methods of treatment with hydroxychloroquine (HCQ). APT recently closed a $9 million Series A financing with Charter Life Sciences, Research Corporation Technologies and Vivo Ventures. The financing positions APT to continue its pulmonary product development program with Aradigm. ( www.aptbio.com )
APT Pharmaceuticals Inc.
APT Pharmaceuticals Inc. 101 N. Wilmot Rd., Suite 600
Tucson, Arizona 85711-3365
USA
Tel: (520) 748-4417
Fax: (520) 748-0025